Talk:Roivant Sciences
![]() | Companies Unassessed | ||||||||||||||||
|
![]() | The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE.
|
![]() | Individuals with a conflict of interest, particularly those representing the subject of the article, are strongly advised not to directly edit the article. See Wikipedia:Conflict of interest. You may request corrections or suggest content here on the Talk page for independent editors to review, or contact us if the issue is urgent. |
Possible Edits
I have a COI with the company , but would like to suggest some factual edits/corrections below. Thanks!
![]() | It is requested that edits be made to the following semi-protected pages:
This template must be followed by a complete and specific description of the request, that is, specify what text should be removed and a verbatim copy of the text that should replace it. "Please change X" is not acceptable and will be rejected; the request must be of the form "please change X to Y".
The edit may be made by any autoconfirmed user. Remember to change the |
1. There is no comma in “Roivant Sciences, Ltd.” it’s just “Roivant Sciences Ltd.” Source: https://www.sec.gov/Archives/edgar/data/1679082/000119312516727309/d221801dex1011.htm
2. A small grammar correction: It should be “the company’s subsidiaries” not “the companies subsidiaries”
3. There is now a new logo which is on the website and image is here: https://static1.squarespace.com/static/5710e74360b5e95e7434951a/t/58c01b61f7e0abb09ddbdad9/1488984934768/
Also, a lot has changed at the company recently so wanted to include some recent news that might be helpful when editing this page moving forward.
1. Topline data from MINDSET is slated to read out in September. Source: https://www.statnews.com/2017/04/10/axovant-new-ceo-david-hung/
2. Enzyvant developing a therapy for Complete DiGeorge Syndrome. Sources: http://www.dukechronicle.com/article/2017/03/pharmaceutical-company-roivant-sciences-collaborates-with-duke-community-in-drug-research and http://medcitynews.com/2017/04/enzyvant-regenerative-medicine-advanced-therapy-rmat-designation/ and https://endpts.com/ramaswamys-enzyvant-scores-a-double-barreled-fda-commitment-to-help-hustle-a-rare-disease-drug-through-its-bla/
3. Relugolix has generate positive Phase 2 trial data for both uterine fibroids and endometriosis-associated pain. Sources: https://endometriosisnews.com/2017/05/22/myovant-presenta-positive-phase-2-results-relugolix-endometriosis-pain/ and http://www.fiercebiotech.com/biotech/myovant-showcases-positive-relugolix-data-will-pfizer-swoop
4. Dermavant purchased the topical rights to cerdulatinib, a Syk/JAK inhibitor, from Portola Pharmaceuticals. It is also advancing a PDE4 inhibitor in-licensed from Eisai. Source: https://endpts.com/is-biopharmas-midas-man-vivek-ramaswamy-building-a-new-ipo-vehicle-with-dermavant-deal/
Thanks 50.75.206.4 (talk) 20:10, 23 May 2017 (UTC)
- Will fix the typos. If the company wants to upload its logo to the commons, the link to do that is here. Make sure who ever does it grants the proper license.
- With respect to 1 and 3 - we do not present content about health (like early clinical trial results) based on those kind of sources and we do not care about the timing of release of clinical trial data. This is an encyclopedia not the company's website or some investor board. I will look at items 2 and 4. Jytdog (talk) 20:15, 23 May 2017 (UTC)
Some corrections/additions to consider
I have a COI with the company, but would like to give some factual corrections/additions below. Thank you!
![]() | It is requested that an edit be made to the semi-protected article at P. (edit · history · last · links · protection log)
This template must be followed by a complete and specific description of the request, that is, specify what text should be removed and a verbatim copy of the text that should replace it. "Please change X" is not acceptable and will be rejected; the request must be of the form "please change X to Y".
The edit may be made by any autoconfirmed user. Remember to change the |
1. Roivant launched a new subsidiary, Urovant, on June 6, 2017. That company is focused on urologic diseases and its initial drug will be developed for overactive bladder (OAB). Sources: http://www.fiercebiotech.com/biotech/roivant-launches-urovant-phase-3-merck-med and http://fortune.com/2017/06/06/biotech-merck-ramaswamy/ and https://endpts.com/ramaswamy-notches-his-5th-biotech-startup-in-3-years-after-inking-a-deal-with-merck-for-phiii-urology-drug/
2. Two errors on Enzyvant bullet: RVT-802 is being developed for “complete DiGeorge Syndrome” (as opposed to standard “DiGeorge Syndrome”), and the treatment involves “thymus tissue,” not "thyroid tissue” as the article current states. Source: http://medcitynews.com/2017/04/enzyvant-regenerative-medicine-advanced-therapy-rmat-designation/?rf=1
3. For Axovant bullet: intepirdine is being developed for Dementia with Lewy Bodies (DLB) in addition to Alzheimer’s disease (minor point, but it is “Alzheimer’s” disease not “Alzheimers” disease). Sources: http://www.wkyc.com/news/health/lewy-body-dementia-second-most-common-form-of-neurodegenerative-dementia-behind-alzheimers/315225308 and http://www.newsobserver.com/news/local/community/chapel-hill-news/article130991774.html The second article also notes that Axovant is also sponsoring Phase 2 trials looking at whether another drug in its pipeline, nelotanserin, can safely and effectively treat visual hallucinations for patients with with Lewy Body Dementia and REM sleep disorders for patients with DLB. Additional source: http://www.fiercebiotech.com/biotech/early-win-means-phase-3-test-way-for-axovant-s-dementia-drug
4. For Myovant bullet: Myovant does not have a “worldwide license” for relugolix, it has a global license *excluding Japan and certain other Asian countries” (those rights are retained by Takeda). Sources: http://www.fiercebiotech.com/biotech/myovant-showcases-positive-relugolix-data-will-pfizer-swoop and https://www.forbes.com/sites/nathanvardi/2016/10/27/the-woman-at-the-center-of-the-biggest-biotech-ipo-of-the-year/#3f2cbff06b08 and http://www.bioworld.com/content/roivants-myovant-sciences-files-173m-ipo-fund-its-phase-iii-ready-asset
5. For Dermavant bullet: Dermavant has three drugs in development, not two. In addition to the two mentioned, there is an oral caspase-1 inhibitor (RVT-201). The available external sources are admittedly not great, but it is inaccurate to state “As of December 2016 it had two drug candidates” since it already had three at that time. Sources: http://adisinsight.springer.com/drugs/800047675 and http://www.biospace.com/News/dermavant-sciences-announces-licensing-of-topical/442576 (under “About Dermavant Sciences”).
6. Roivant’s new logo can be found here:
![](http://upload.wikimedia.org/wikipedia/commons/thumb/f/f9/Roivant.png/220px-Roivant.png)
50.75.206.4 (talk) 13:34, 15 June 2017 (UTC)
- Wikipedia is not going to be a blow-by-blow update to the various companies' pipelines - that is what their websites are for. I will go back over this and remove some detail so you can stop wasting your time (and ours) with pipeline updates. I fixed the thymus error, thanks for pointing that out. More anon. Jytdog (talk) 13:42, 15 June 2017 (UTC)
Note: Marked as partial. jd22292 (Jalen D. Folf) (talk) 19:16, 11 July 2017 (UTC)
Additions
I have a COI, but wanted to see if someone could add in two things. Thanks
![]() | It is requested that an edit be made to the semi-protected article at P. (edit · history · last · links · protection log)
This template must be followed by a complete and specific description of the request, that is, specify what text should be removed and a verbatim copy of the text that should replace it. "Please change X" is not acceptable and will be rejected; the request must be of the form "please change X to Y".
The edit may be made by any autoconfirmed user. Remember to change the |
1. Roivant launched a new subsidiary, Urovant, on June 6, 2017. That company is focused on urologic diseases and its initial drug will be developed for overactive bladder (OAB). Sources: http://www.fiercebiotech.com/biotech/roivant-launches-urovant-phase-3-merck-med http://fortune.com/2017/06/06/biotech-merck-ramaswamy/ https://endpts.com/ramaswamy-notches-his-5th-biotech-startup-in-3-years-after-inking-a-deal-with-merck-for-phiii-urology-drug/ http://www.pharmaceutical-technology.com/news/newsroivant-forms-new-subsidiary-to-develop-urology-therapies-5836970
2. Could we add the CEOs of Roivant’s subsidiaries: Enzyvant: Alvin Shih Source: https://techcrunch.com/2017/01/06/this-millennial-wants-to-build-the-berkshire-hathaway-of-biopharmaceutical-companies-can-he-pull-it-off/ Myovant CEO: Lynn Seely Source: https://techcrunch.com/2017/01/06/this-millennial-wants-to-build-the-berkshire-hathaway-of-biopharmaceutical-companies-can-he-pull-it-off/ Axovant: David Hung Source: https://www.wsj.com/articles/the-400-million-man-1491838810 Dermavant: Jackie Fouse Source: http://fortune.com/2017/07/10/biotech-celgene-roivant-ceo/
207.38.201.53 (talk) 12:20, 6 August 2017 (UTC)
- Did the urovant thing; the CEOs are UNDUE here. 01:38, 7 August 2017 (UTC)
Another addition for consideration:
Could we also add Datavant to the subsidiaries section? Datavant is a new technology-focused subsidiary aimed at using artifical intelligence (AI) to unlock insights in health care datasets. Datavant is the first company in the Roivant family to operate outside of traditional biopharmaceutical development.
Sources: https://techcrunch.com/2017/08/09/roivant-which-creates-companies-around-orphaned-drugs-just-raised-1-1-billion-from-softbank/?ncid=rss and https://www.wired.com/story/softbank-invests-roivant/ 50.75.206.4 (talk) 16:08, 24 August 2017 (UTC)
- Both of those refs talk about plans, not about Datavant actually being created already. Jytdog (talk) 21:04, 24 August 2017 (UTC)
- Here is another article that points to the launch of Datavant including its new CEO Travis May. Source: https://endpts.com/tech-maven-travis-may-takes-the-helm-of-roivants-data-mining-startup/ 50.75.206.4 (talk) 15:34, 2 October 2017 (UTC)
Updates
I have a COI with the company but I noticed the article is out of date and wanted to suggest a series of edits to be implemented. Thank you.
1. Roivant licenses more than “late-stage” drug candidates (see Genevant, Axovant gene therapy deals below), so more accurate to say “a company that in-licenses investigational drugs and develops them through subsidiaries.”
2. The company and its affiliates now have offices in:
a. San Francisco, C.A. Source: https://www.xconomy.com/national/2018/01/08/axovant-neuro-drug-stumbles-and-falls-in-phase-2-shares-drop-50/
b. San Diego, C.A. Source: https://www.fiercebiotech.com/biotech/roivant-launches-lung-focused-respivant-phase-2-ipf-drug
c. Irvine, C.A. Source: https://www.fiercebiotech.com/biotech/urovant-poaches-allergan-urology-head-as-new-cmo
d. Brisbane, C.A. Source: http://www.finsmes.com/2017/08/roivant-sciences-raises-1-1-billion-in-equity-funding.html
e. Cambridge, M.A. Source: https://www.forbes.com/sites/matthewherper/2018/07/09/vivek-ramaswamys-enzyvant-asks-fda-to-approve-treatment-for-dying-babies/#6fa8c2211007
f. China (Beijing and Shanghai). Source: https://endpts.com/vivek-ramaswamy-strikes-again-this-time-launching-a-beijing-based-biotech-player-with-a-pipeline/
g. Canada (Vancouver) Source: https://www.biospace.com/article/another-notch-on-the-belt-as-ramaswamy-launches-genevant/
3. New subsidiary launched: Datavant. Aims to “de-silo different data sets across healthcare.” Source: https://endpts.com/what-do-you-get-when-you-integrate-healthcare-data-from-multiple-sources-into-one-comprehensive-global-package-travis-may-says-hes-on-track-to-find-out/
4. New subsidiary launched: Sinovant “aimed at developing innovative treatments for some of China’s most pressing medical concerns.” Launched with a pipeline of 11 investigational biopharmaceutical products for Greater China and other Asian markets, including four therapies suitable for Phase III clinical trial application or registration in China. Source: https://www.biospace.com/article/roivant-launches-new-china-based-startup-sinovant-sciences/
5. New subsidiary launched: Respivant “built around an inhaled drug for treating chronic cough in patients with idiopathic pulmonary fibrosis.” Source: https://www.fiercebiotech.com/biotech/roivant-launches-lung-focused-respivant-phase-2-ipf-drug
6. New subsidiary launched: Genevant “working on a range of RNA-based therapeutics backed by Arbutus’ proprietary lipid nanoparticle and ligand conjugate delivery technologies.” Source: https://endpts.com/vivek-ramaswamy-is-diving-into-rna-launching-a-new-biotech-with-arbutus-and-a-team-of-vets/
7. New subsidiary launched: Metavant a “cardiometabolic disease startup” which holds rights to glucagon receptor antagonist and an oral oxidative phosphorylation blocker. Source: https://www.fiercebiotech.com/biotech/roivant-licenses-ligand-diabetes-drug-founds-metavant-as-push-into-cardiometabolic-diseases
8. New subsidiary launched: Immunovant, built around “a fully human monoclonal antibody targeting the neonatal Fc receptor.” Source: https://www.biospace.com/article/roivant-taps-genentech-veteran-as-operating-chair-ahead-of-pipeline-day/
9. New subsidiary launched: Altavant, built around “a possible treatment for pulmonary arterial hypertension and other indications.” Source: https://www.biospace.com/article/big-shakeup-and-restructuring-at-vivek-ramaswamy-s-roivant-companies/
10. After discontinuing intepirdine, Axovant has licensed several investigational gene therapies for Parkinson’s disease, oculopharyngeal muscular dystrophy, and other conditions. Source: https://endpts.com/focused-on-rebuilding-the-pipeline-axovants-new-crew-assembles-another-preclinical-gene-therapy-deal/; https://endpts.com/picking-up-the-pieces-left-from-an-alzheimers-implosion-axovant-is-starting-over-by-diving-into-gene-therapy/
11. Add “biopharmaceutical” to industry listing as subsidiary companies such as Genevant and Immunovant are operating in that space (i.e. biotech rather than conventional pharmaceutical)
12. Update leadership:
a. Add: Myrtle Potter, Dr. Frank Torti, Adele Gulfo, Sam Azoulay, Ben Zimmer, Allen Waxman. Source: https://endpts.com/genentech-vet-myrtle-potter-takes-a-leading-role-in-vivek-ramaswamys-fast-moving-vant-ops/; https://www.fiercebiotech.com/biotech/roivant-appoints-nea-partner-frank-torti-as-overseer-its-vant-subsidiaries; https://www.fiercebiotech.com/biotech/ex-pfizer-execs-join-roivant-s-c-suite; https://www.biospace.com/article/big-shakeup-and-restructuring-at-vivek-ramaswamy-s-roivant-companies/; https://endpts.com/lundbeck-ceo-bags-20m-bonus-jumping-ship-for-teva-helm/
b. Remove: Dr. Lawrence Friedhoff, William Symonds, Marianne Romeo (employed but not senior leadership and not listed in the cited article)
13. Financing history (if including SoftBank might make sense to list earlier rounds):
a. May 2014 seed round - $93 million lead by QVT Financial, included Dexcel Pharma. Source: https://techcrunch.com/2017/08/09/roivant-which-creates-companies-around-orphaned-drugs-just-raised-1-1-billion-from-softbank/;
b. December 2015 PE/Growth round - $500 million lead by Viking Global. Source: https://www.forbes.com/sites/nathanvardi/2016/07/13/billionaire-andreas-halvorsens-hedge-fund-backs-private-biotech-roivant-sciences/#5fa85b892455
c. August 2017 PE/Growth round - $1.1 billion lead by Softbank Vision Fund, with participation from Founders Fund. Source: https://techcrunch.com/2017/08/09/roivant-which-creates-companies-around-orphaned-drugs-just-raised-1-1-billion-from-softbank/
14. In June 2018 Roivant laid off 67 employees, not 70. source: https://www.fiercebiotech.com/roivant-lays-off-staff-reassigns-others-major-reshuffle
15. Add in the logo picture that I’ve uploaded to wiki commons linked here: https://commons.wikimedia.org/wiki/File:Roivant_Logo.png
— Preceding unsigned comment added by 136.24.120.116 (talk) 22:50, 12 October 2018 (UTC)
Update Requests
I've recently been asked by Roivant Sciences to look over their page and to try to get their recent edit requests implemented. I'm hoping that these requests can be implemented by the many active editors I see on the page and I'm certainly open for any discussions about making this page more accurate and up-to-date. Thank you for any help with this project! FinalFrontier.003 (talk) 10:36, 31 October 2018 (UTC)
Extended content
|
---|
References
|
Editing
I've recently started to implement some of the changes I outlined above as a stated COI editor. I'd love feedback and discourse to help the page stay current and accurate. Thanks! FinalFrontier.003 (talk) 08:11, 6 November 2018 (UTC)
Edit requests from COI editor
![]() | It is requested that edits be made to the following semi-protected pages:
This template must be followed by a complete and specific description of the request, that is, specify what text should be removed and a verbatim copy of the text that should replace it. "Please change X" is not acceptable and will be rejected; the request must be of the form "please change X to Y".
The edit may be made by any autoconfirmed user. Remember to change the |
I accidentally made these changes as a COI editor recently and now understand that I need to submit them for review and to have them implemented by all of you. I'd appreciate assistance with these changes and a conversation about what may work and what may not.
Extended content
|
---|
I'd like this paragraph updated. Reference remains the same.
References
|
FinalFrontier.003 (talk) 07:43, 14 November 2018 (UTC)
Reply 14-NOV-2018
Edit request partially implemented
The Urovant paragraph was updated.
The proposed additional text was not added, as it contained unattributed quoted material. Quotes must be properly attributed, per MOS:QUOTE.
- The paragraph concerning Datavent was omitted, as its text was insufficiently paraphrased from the source material. All added text must be placed in an editor's own words and phrasing, per WP:CLOSEPARAPHRASE.
- The use of they when referring to the company was changed to the company.
- The use of Dr. when referring to the company's leadership was omitted, per MOS:DOCTOR.
- Punctuation which followed ref notes was moved to precede ref notes, per MOS:PUNCTREF.
Regards, Spintendo 12:59, 14 November 2018 (UTC)
Edit requests from COI editor
![]() | It is requested that edits be made to the following semi-protected pages:
This template must be followed by a complete and specific description of the request, that is, specify what text should be removed and a verbatim copy of the text that should replace it. "Please change X" is not acceptable and will be rejected; the request must be of the form "please change X to Y".
The edit may be made by any autoconfirmed user. Remember to change the |
I’m resubmitting these requests with rewording, being careful not to have unattributed quotes or paraphrased materials from source material. I’ve also asked for a few small wording changes that are new. I appreciate all assistance and feedback on these ideas.
Extended content
|
---|
References
|
Thanks!FinalFrontier.003 (talk) 07:26, 18 November 2018 (UTC)
Reply to edit request 20-NOV-2018
Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes within the proposal review section below for information on each request. Spintendo 08:05, 20 November 2018 (UTC)
Proposal review 20-NOV-2018
|
---|
|
Edit request: COI editor
![]() | It is requested that edits be made to the following semi-protected pages:
This template must be followed by a complete and specific description of the request, that is, specify what text should be removed and a verbatim copy of the text that should replace it. "Please change X" is not acceptable and will be rejected; the request must be of the form "please change X to Y".
The edit may be made by any autoconfirmed user. Remember to change the |
I’m requesting a few more edits as a COI editor and I look forward to your feedback.
Extended content
|
---|
References
|
Thank you! FinalFrontier.003 (talk) 04:09, 5 December 2018 (UTC)
Reply to edit request 05-DEC-2018
Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes within the proposal review section below for information on each request. Spintendo 10:55, 5 December 2018 (UTC)
Proposal review 05-DEC-2018
|
---|
|
Edit request
![]() | It is requested that edits be made to the following semi-protected pages:
This template must be followed by a complete and specific description of the request, that is, specify what text should be removed and a verbatim copy of the text that should replace it. "Please change X" is not acceptable and will be rejected; the request must be of the form "please change X to Y".
The edit may be made by any autoconfirmed user. Remember to change the |
In my last edit request, I received feedback from @Spintendo: that I needed to find references from outside of the pharmaceutical space. I'm including the sentences I'd like added with the references I've found. Thanks for your help, Spintendo and anyone else who might help me here.
Extended content
|
---|
References
|
FinalFrontier.003 (talk) 07:12, 16 December 2018 (UTC)
Reply 16-DEC-2018
Additional references requested
- The references from Parkinson's News Today and Muscular Dystrophy News Today are not unconnected to the pharmaceutical industry.
- The reference labeled BBC World Service is actually a Cincinnati-based NPR affiliate reporting on claims affecting a business, Cincinnati Children’s Hospital Medical Center (CCHMC) which operates in Cincinnati. There exists a connection between the radio station and its listener market on one side and Aruvent on the other, who are subsidiaries of Roivant. Just as local stories in a city have a pull on the reporting resources of a station operating within the same city, this radio station is not independent when it is reporting on a story about a company operating in the same city the radio station operates in.
Please provide secondary sources which are unconnected to either side of the actors involved here — both Roivant / the pharmaceutical industry and CCHMC. Regards, Spintendo 15:30, 16 December 2018 (UTC)
Offering other sources
![]() | It is requested that an edit be made to the semi-protected article at A. (edit · history · last · links · protection log)
This template must be followed by a complete and specific description of the request, that is, specify what text should be removed and a verbatim copy of the text that should replace it. "Please change X" is not acceptable and will be rejected; the request must be of the form "please change X to Y".
The edit may be made by any autoconfirmed user. Remember to change the |
Trying again to hit the nail on the head with the type of references requested by @Spintendo:. I'm including the sentences I'd like added with the references I've found. Thanks for your help, Spintendo, and anyone else who might help me here.
Extended content
|
---|
References
|
FinalFrontier.003 (talk) 10:00, 17 December 2018 (UTC)
Reply 18-DEC-2018
- Despite the direction to place the first claim "after reference 21", the claim was placed under the same bullet point as other information regarding Axovent, after ref tag number #20.
Regards, Spintendo 16:13, 18 December 2018 (UTC)
Request to add one subsidiary
![]() | It is requested that an edit be made to the semi-protected article at A. (edit · history · last · links · protection log)
This template must be followed by a complete and specific description of the request, that is, specify what text should be removed and a verbatim copy of the text that should replace it. "Please change X" is not acceptable and will be rejected; the request must be of the form "please change X to Y".
The edit may be made by any autoconfirmed user. Remember to change the |
I'd like to request that one sentence be added to the list of subsidiaries.
Extended content
|
---|
References
|
FinalFrontier.003 (talk) 09:36, 7 January 2019 (UTC)
Reply 07-JAN-2019
- Please clarify what is meant by therapeutic focus, per MOS:IDIOM. As a rule, items which are explainable through brevity may often be clouded by vagueness. Please describe in what way the company focuses on PAH and what it is about that focus that makes the mentioning of its work necessary for the article. This enhanced explanation may help readers who are not familiar with disease states and how companies who treat them describe this attention as a "focusing" of their activities.[a]
Regards, Spintendo 01:04, 8 January 2019 (UTC)
Notes
- ^ The language of "focusing" is one used by select industries, such as healthcare, but is foreign to many other industries where the term is not used (i.e., a gardener does not "focus on weed extraction", etc.) The meaning should be made more clear to readers.
![]() | It is requested that an edit be made to the semi-protected article at A. (edit · history · last · links · protection log)
This template must be followed by a complete and specific description of the request, that is, specify what text should be removed and a verbatim copy of the text that should replace it. "Please change X" is not acceptable and will be rejected; the request must be of the form "please change X to Y".
The edit may be made by any autoconfirmed user. Remember to change the |
I'm resubmitting my request to add one sentence. I've tried to clarify what a "therapeutic focus" means. Thanks!
Extended content
|
---|
References
|
FinalFrontier.003 (talk) 07:37, 10 January 2019 (UTC)
Reply 10-JAN-2019
- Thank you for the change in tone for this claim. By using plain-spoken non-industry preferred language, the claim seems more informational as a news item and less like part of a brochure for the company.
- The word new as in "new treatment" was omitted per MOS:RELTIME.
Regards, Spintendo 11:06, 10 January 2019 (UTC)
Edit request
![]() | It is requested that edits be made to the following semi-protected articles:
This template must be followed by a complete and specific description of the request, that is, specify what text should be removed and a verbatim copy of the text that should replace it. "Please change X" is not acceptable and will be rejected; the request must be of the form "please change X to Y".
The edit may be made by any autoconfirmed user. Remember to change the |
I'd like to request that one sentence be added to the list of subsidiaries.
Extended content
|
---|
References
|
Thank you! FinalFrontier.003 (talk) 06:57, 23 January 2019 (UTC)
Reply 23-JAN-2019
- Extraordinary claims require extraordinary references. "Reducing the cost of commercializing medicines" is just such a claim. Please provide references from reliable secondary and third-party sources.
Regards, Spintendo 07:15, 23 January 2019 (UTC)
- @Spintendo: I certainly understand what you are saying, but I would argue that this company exists (as we know) and has a plan (which makes readers understand what their purpose is). I offer a few ideas, but the third idea leaves the reader without a clear understanding of the company's purpose. In terms of references (as we've discussed in the past) it's a biotech company and is being written up in biotech, pharmaceutical and medical publications. These are all the available references at this time.
Extended content
|
---|
References
|
Thank you for all of your assistance and input, FinalFrontier.003 (talk) 09:13, 23 January 2019 (UTC)
Revised edit request
![]() | This edit request has been answered. Set the |answered= or |ans= parameter to no to reactivate your request. |
In response to the feedback I received to my last edit request for Roivant Sciences, I have formulated the sentence I would like added in a new way. This is intended to be added at the end of the list of subsidiaries.
Extended content
|
---|
Here are three suggestions that I'm making. I'd prefer to have the first sentence used, but I've written sentences 2 and 3 as alternatives depending on what the editor finds most acceptable. I don't have any other references to offer at this time. It's a biotech company and is being written up in biotech, pharmaceutical and medical publications.
or
or References
|
Thank you for any assistance you can offer, FinalFrontier.003 (talk) 06:54, 27 January 2019 (UTC)
- As the company was only just recently created, any discussion about "what it was formed to do" is to describe a future, hoped-for state of affairs. When a claim is from a company regarding its plans for itself in the future, the claim is not about what was — rather, it discusses what will be — which cannot be done, per WP:NOTACRYSTALBALL. If the company was formed, then that can be mentioned. What the plans are for the company are claims about the future, and cannot be included using Wikipedia's voice. In order to include this claim, the language needs to specify that it is the company itself which is making these claims about its future self (i.e., "Alyvant was formed in January 2019. The company has stated that its goal is to enhance exchanges of information between patients and their physicians" versus "Alyvant was formed in January 2019 to connect patient and physician data."). This improved wording should be referenced by reliable WP:SECONDARY sources unconnected to the company itself.[a] Spintendo 11:40, 27 January 2019 (UTC)
Notes
References
Edit to intro
![]() | This edit request has been answered. Set the |answered= or |ans= parameter to no to reactivate your request. |
I'm requesting a change in the first sentence of the article where it says: Roivant Sciences Ltd. is a pharmaceutical company that in-licenses late-stage drug candidates and develops them through subsidiaries. The wording "late-stage" is not accurate since they have some companies with early stage assets like Axovant, Genevant and Enzyvant (to name a few) and other companies with other focuses in the healthcare space. I'd like to propose that we remove the wording "late-stage" so that the sentence would read "Roivant Sciences Ltd. is a pharmaceutical company that in-licenses drug candidates and develops them through subsidiaries." I can provide other references, if needed, but I think the current ones speak to this change sufficiently. Thank you for any assistance FinalFrontier.003 (talk) 07:13, 13 February 2019 (UTC)
Reply 14-FEB-2019
- When the term late-stage was originally added in 2016, the statement it appeared in was worded as such:
"Roivant does this by looking for promising drugs that are not being developed by other biopharmaceutical companies due to financial reasons or commercial alignments, and takes those drugs from where they were left off in late-stage clinical development and brings them through the final stages of approval.
Please confirm whether or not this is still the case so that the sentence may either be clarified or omitted. When ready to proceed with the requested information, kindly change the{{request edit}}
template's answer parameter to read from|ans=yes
to|ans=no
. Thank you!
Regards, Spintendo 10:28, 14 February 2019 (UTC)
- Thank you for your diligence @Spintendo: The answer to your question is as follows. While the current wording was true at the time, Roivant’s pipeline and business model have expanded significantly since. Their mission is to deliver innovative medicines and technologies to patients and they have moved away from solely late stage clinical development. Notably, they've in-licensed a number of medicines that fall outside of the traditional early stage/late stage drug development paradigm, such as gene therapy assets for Aruvant, Axovant, and Urovant or RNA therapeutic platform for Genevant. Additionally, their subsidiaries Datavant and Alyvant, focused on health data and patient analytics respectively, operate outside of the biopharmaceutical company model. Because of the developments, they believe that there is space for greater clarification in how the statement is currently phrased. I look forward to your reply FinalFrontier.003 (talk) 07:17, 17 February 2019 (UTC)
- Thank you for your reply. Based on your answer, the question of what to do here seems simple enough, in that the sentence should be re-worded to state that Roivant originally dealt in "late stage" clinical development, but now operates in an otherwise configuration. Spintendo 14:18, 18 February 2019 (UTC)
- Thank you for your diligence @Spintendo: The answer to your question is as follows. While the current wording was true at the time, Roivant’s pipeline and business model have expanded significantly since. Their mission is to deliver innovative medicines and technologies to patients and they have moved away from solely late stage clinical development. Notably, they've in-licensed a number of medicines that fall outside of the traditional early stage/late stage drug development paradigm, such as gene therapy assets for Aruvant, Axovant, and Urovant or RNA therapeutic platform for Genevant. Additionally, their subsidiaries Datavant and Alyvant, focused on health data and patient analytics respectively, operate outside of the biopharmaceutical company model. Because of the developments, they believe that there is space for greater clarification in how the statement is currently phrased. I look forward to your reply FinalFrontier.003 (talk) 07:17, 17 February 2019 (UTC)
Request edit 20-FEB-2019
![]() | It is requested that an edit be made to the semi-protected article at A. (edit · history · last · links · protection log)
This template must be followed by a complete and specific description of the request, that is, specify what text should be removed and a verbatim copy of the text that should replace it. "Please change X" is not acceptable and will be rejected; the request must be of the form "please change X to Y".
The edit may be made by any autoconfirmed user. Remember to change the |
In response to my discussion with @Spintendo: I've come up with language that should meet all of the requirements for the first sentence of the article. It currently says "Roivant Sciences Ltd. is a pharmaceutical company that in-licenses late-stage drug candidates and develops them through subsidiaries." I propose that the language be changed to say: Roivant Sciences Ltd. is a biopharmaceutical company that builds subsidiary biotech and health technology companies.[1][2] The company’s initial strategy was in-licensing late-stage drug candidates but has since expanded its business model to develop earlier stage drug candidates and other healthcare technologies. [3] [4][5] Thank you for your consideration FinalFrontier.003 (talk) 09:54, 20 February 2019 (UTC)
References
- ^ Vardi, Nathan (13 July 2016). "Billionaire Andreas Halvorsen's Hedge Fund Backs Private Biotech Roivant Sciences". Forbes. Retrieved 2016-10-07.
- ^ Vardi, Nathan (9 September 2015). "The 30-Year-Old CEO Conjuring Drug Companies From Thin Air". Forbes. Retrieved 2016-10-07.
- ^ Spalding, Rebecca. "SoftBank-Backed Biotech Roivant Climbs to $7 Billion Valuation". Bloomberg. Retrieved 20 February 2019.
- ^ Terry, Mark. "Roivant Sciences Raises $200 Million, Bringing Its Valuation to $7 Billion". Biospace. Retrieved 20 February 2019.
- ^ Rogers, Adam. "A Japanese Telecom Giant Bets $1 Billion on Pharma". Wired. Retrieved 20 February 2019.
Reply 20-FEB-2019
Edit request implemented Spintendo 10:09, 20 February 2019 (UTC)
- Thank you for your help @Spintendo:! FinalFrontier.003 (talk) 06:05, 21 February 2019 (UTC)